# SAD and MAD Study of FTX-101 in Healthy Male Subjects

> **NCT06617546** · PHASE1 · TERMINATED · sponsor: **Find Therapeutics** · enrollment: 49 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** FTX-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06617546
- **Lead sponsor:** Find Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-14
- **Primary completion:** 2025-04-17
- **Final completion:** 2025-04-17
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Study's goals have been achieved based on a preliminary analysis of available pharmacokinetic and safety data, which demonstrate that sufficient information has been obtained.
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06617546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06617546, "SAD and MAD Study of FTX-101 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06617546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*